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Abstract
Objective—To examine the association between early HIV viremia and mortality after HIV-
associated lymphoma.
Design—Multicenter observational cohort study.
Setting—Center for AIDS Research Network of Integrated Clinical Systems cohort.
Subjects—HIV-infected patients with lymphoma diagnosed between 1996 and 2011, who were
alive 6 months after lymphoma diagnosis and with ≥2 HIV RNA values during the 6 months after
lymphoma diagnosis.
Exposure—Cumulative HIV viremia during the 6 months after lymphoma diagnosis, expressed
as viremia copy-6-months.
Main outcome measure—All-cause mortality between 6 months and 5 years after lymphoma
diagnosis.
Results—Of 224 included patients, 183 (82%) had non-Hodgkin lymphoma (NHL) and 41
(18%) had Hodgkin lymphoma (HL). At lymphoma diagnosis, 105 (47%) patients were on
antiretroviral therapy (ART), median CD4 count was 148 cells/µlL (IQR 54– 322), and 33% had
suppressed HIV RNA (<400 copies/mL). In adjusted analyses, mortality was associated with older
age [adjusted hazard ratio (AHR) 1.37 per decade increase, 95% CI 1.03–1.83], lymphoma
occurrence on ART (AHR 1.63, 95% CI 1.02– 2.63), lower CD4 count (AHR 0.75 per 100 cell/µL
increase, 95% CI 0.64–0.89), and higher early cumulative viremia (AHR 1.35 per log10copies ×
6-months/mL, 95% CI 1.11–1.65). The detrimental effect of early cumulative viremia was
consistent across patient groups defined by ART status, CD4 count, and histology.
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Conclusions—Exposure to each additional 1-unit log10 in HIV RNA throughout the 6 months
after lymphoma diagnosis, was associated with a 35% increase in subsequent mortality. These
results suggest that early and effective ART during chemotherapy may improve survival.
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Introduction
In resource-rich settings, cancer is the leading cause of death among HIV-infected persons
in the modern antiretroviral therapy (ART) era, and lymphoma the most frequent cancer-
related cause [1–4].
Effects of ART early after HIV-associated lymphoma diagnosis remain uncertain.
Chemotherapy clinical trials conducted by the National Cancer Institute (NCI) and AIDS
Malignancy Consortium (AMC) have employed various strategies with respect to ART
without directly comparing approaches. Strategies have included concurrent ART during
chemotherapy [5,6], ART suspension until chemotherapy completion [7,8], or ART left to
physicians’ discretion [9]. Potential negative effects of concurrent ART during
chemotherapy include overlapping toxicities, medication interactions [10,11], antiapoptotic
ART effects [10,12,13], and HIV resistance from ART interruption [10].
Similar concerns previously existed regarding ART during treatment for opportunistic
infections (OIs), including toxicities and interactions, ART discontinuity and HIV
resistance, and risk of the immune reconstitution inflammatory syndrome (IRIS). However,
multiple randomized clinical trials have demonstrated that deferring ART by even several
weeks worsens outcomes for patients with OIs, particularly when severely
immunosuppressed, with cryptococcal and tuberculous meningitis being possible exceptions
[14–19]. A similar detrimental effect of deferred ART is possible for HIV-associated
lymphoma patients, who present with significant immunosuppression even in the ART era
[5– 9,20,21]. Additionally, Epstein-Barr virus (EBV) is present in approximately 40% of
tumors with marked variation by histologic subtype [10]. For EBV-associated lymphomas,
early immune reconstitution may improve outcomes, analogous to EBV-associated post-
transplant lymphoproliferative disease (PTLD), for which prompt reduction of
immunosuppression may obviate need for chemoimmunotherapy [22].
Reflecting these controversies, consensus guidelines make no strong recommendation for or
against concurrent ART during chemotherapy [22]. We studied a large United States cohort
of HIV-infected lymphoma patients who survived at least six months after lymphoma




The Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)
cohort has been described elsewhere [23]. CNICS provides a clinical data repository from
electronic medical record systems. CNICS includes over 25,000 HIV-infected adults older
than 18 years, receiving care from January 1, 1995 to the present, at eight CFAR sites
throughout the United States (Case Western Reserve University; University of Alabama at
Birmingham; University of California, San Francisco; University of Washington; University
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of California, San Diego; Fenway Health, affiliated with Harvard University; University of
North Carolina; Johns Hopkins University).
We examined individuals in CNICS with non-Hodgkin lymphoma (NHL) or Hodgkin
lymphoma (HL) diagnosed between January 1, 1996 and December 31, 2011. If more than
one lymphoma diagnosis or relapse was recorded for a single patient, we analyzed only the
first occurrence. For inclusion, patients were additionally required to have at least two
unique HIV RNA measurements taken at least one month apart, during the time interval
between one month before and seven months after lymphoma diagnosis. To avoid excluding
patients with HIV RNA values taken just before or after the six-month window of interest
following lymphoma diagnosis, a one-month tail was included on either side. Patients were
also required to be at risk for mortality beginning six months after lymphoma diagnosis (i.e.
not deceased, lost to follow-up, or administratively censored prior to this time point). All
inclusion criteria were intended to allow reliable assessment of the principal exposure of
interest, cumulative HIV viremia during the six months after lymphoma diagnosis.
Procedures
Upon CNICS entry, standardized demographic and historical information, including prior
diagnoses and antiretroviral treatment, are collected. Data including medications, laboratory
values, and AIDS-defining and non-AIDS-defining conditions, are prospectively collected
and verified by medical record review. A standardized cancer diagnosis verification
procedure has been established [24]. Incident cancers are reviewed for confirmation and to
collect information regarding type, histology, staging, and treatment. Patients must attend
HIV clinics at network sites to be enrolled, although data may be available from electronic
medical records prior to cohort entry. Mortality data are obtained from clinic sources and
confirmed by the Social Security Death Index (SSDI). CD4 count and HIV RNA at
lymphoma diagnosis were defined as values closest to diagnosis date beginning three
months before until three months after. Nadir CD4 count was defined as the lowest CD4
count at any time on or before the date of CD4 at lymphoma diagnosis. Undetectable HIV
RNA was assigned a value equal to half the detection limit of the assay. Suppressed HIV
RNA was defined as less than 400 copies/mL. Hepatitis B co-infection was defined as any
positive hepatitis B surface antigen or DNA result, and hepatitis C co-infection as any
positive hepatitis C antibody or RNA result, before or until six months after lymphoma
diagnosis. Lymphoma developing on ART was defined as receipt of any antiretroviral
medication from six months to one month before lymphoma diagnosis. Patients with ART
exposure ending more than six months prior to lymphoma diagnosis, or ART initiated within
one month prior to lymphoma diagnosis, were classified as being off ART at lymphoma
diagnosis.
Statistical analysis
We assessed cumulative HIV viremia using the viremia copy-years method [25,26]. Given
the six-month window of interest, we adapted this to define our principal exposure as
viremia copy-6-months. This is a measure of cumulative HIV viremia during the six months
after lymphoma diagnosis, similar to smoking pack-years. The trapezoidal rule is used to
approximate the integral representing the area under the longitudinal HIV RNA curve for
each patient. HIV RNA burden for each time interval between two consecutive HIV RNA
values is calculated by multiplying the mean of the two values by the time interval. The
copy x 6-months/mL values for each segment of a patient’s HIV RNA curve are then
summed to calculate viremia copy-6-months. For instance, having a viremia copy-6-months
value of 3 log10copies x 6-months/mL is equivalent to having an HIV RNA of 1000 copies/
mL for six months, or an HIV RNA of 2000 copies/mL for two months followed by 500
copies/mL for four months. If the first HIV RNA measure occurred before lymphoma
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diagnosis, this was carried forward to the lymphoma diagnosis date. If the first HIV RNA
measure occurred after lymphoma diagnosis, this was carried backward to the lymphoma
diagnosis date. Similarly, if the last HIV RNA measure occurred prior to six months after
lymphoma diagnosis, this was carried forward, and if the last HIV RNA measure occurred
after, it was carried backward to the six-month time point. For all patients, area under the
HIV RNA curve was calculated for the entire six-month window of interest. We additionally
examined effects of cross-sectional HIV RNA measures at lymphoma diagnosis and six
months after.
Differences in proportions, means, and medians for patients developing lymphoma on and
off ART were assessed using chi-square or Fisher’s exact tests, one-way analysis of variance
(ANOVA), and Kruskal-Wallis tests, respectively. HIV RNA curves for patients on and off
ART at lymphoma diagnosis were constructed by taking the median HIV RNA value across
all patients at each monthly time point. HIV RNA values for individual patients at each
monthly time point were assigned based on the value at which the individual’s HIV RNA
curve intersected each time point similar to the segmental viremia copy-years method
described above. Follow-up time was calculated beginning six months after lymphoma
diagnosis until administrative censoring, death, or loss to follow-up. Follow-up was
administratively censored on December 31, 2011. Loss to follow-up was assigned based on
last date of any clinical activity in CNICS. Mortality rates were calculated as the number of
deaths per 100 person-years of follow-up. Kaplan-Meier cumulative mortality curves were
used to estimate probability of death beginning six months after lymphoma diagnosis.
Differences in cumulative mortality across viremia-6-months categories were evaluated
using the log-rank test. Cox proportional hazards modeling was used to estimate the
relationship between viremia copy-6-months and mortality, adjusted for sex, race/ethnicity,
age, lymphoma diagnosis year, hepatitis B or C co-infection, prior AIDS-defining illness,
ART status, CD4 count, and histology. All analyses were conducted using SAS version 9.2.
A two-sided alpha value of 0.05 was used to assess statistical significance. Patients were
excluded from analyses which included variables for which data were missing.
Results
Of 24,203 HIV-infected individuals enrolled in CNICS, 482 (2%) individuals were
diagnosed with lymphoma between 1996 and 2011. Of these, 224 (46%) patients met all
criteria for study inclusion. Among excluded patients were 192 (40%) patients lacking at
least two distinct HIV RNA measurements from one month before until seven months after
diagnosis, as well as 66 (14%) patients who were not at risk for mortality six months after
diagnosis when individuals began to contribute follow-up time. Of these 66 patients, 44 died
before six months, 9 were censored before six months, and 13 were not officially enrolled in
CNICS until more than six months after lymphoma diagnosis.
The final analytic population had a median age of 43 years [interquartile range (IQR) 38–
49], 92% were male, 52% were white, and 79% had prior AIDS-defining illnesses.
Histologic distribution was 41 (18%) HL, 106 (47%) diffuse large B-cell lymphoma
(DLBCL), 27 (12%) Burkitt lymphoma (BL), 18 (8%) primary CNS lymphoma (PCNSL),
and 32 (14%) other NHL. At lymphoma diagnosis, median CD4 count was 148 cells/ mL
(IQR 54–322), median nadir CD4 count was 73 cells/mL (IQR 28–177), median HIV RNA
was 3.99 log10copies/mL (IQR 2.26–5.16), and the proportion of patients with suppressed
HIV RNA was 33%. CD4 count and HIV RNA measurements at lymphoma diagnosis
differed from the diagnosis date by a median of 12 days (IQR 4–25) and 12 days (IQR 4–26)
respectively. During the exposure window of interest, patients contributed a median of three
HIV RNA measures (IQR 2–4), for a total of 667 measures for the entire study population.
The median viremia copy-6-months value for the entire study population was 2.68
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log10copies x 6-months/mL (IQR 1.85–3.94). There were 64 (29%) patients who had
suppressed HIV RNA throughout the six-month exposure window of interest.
At lymphoma diagnosis, 105 (47%) patients were on ART for a median duration of 14.7
months (IQR 5.1–36.6). Three months after lymphoma diagnosis 129 (58%) were on ART
[48 of 119 (37%) of those off ARTat lymphoma diagnosis; 81 of 105 (63%) of those on
ARTat lymphoma diagnosis]. Six months after lymphoma diagnosis 158 (71%) were on
ART [73 of 119 (61%) of those off ART and 85 of 105 (81%) of those on ART at
lymphoma diagnosis]. For patients on ART at lymphoma diagnosis, ART was protease
inhibitor (PI)-based for 49 (47%) patients, non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based for 40 (38%), integrase inhibitor (II)-based for 4 (4%), and another regimen
for 12 (11%). For patients off ART, the first ART initiated after lymphoma diagnosis was
PI-based for 57 (48%) patients, NNRTI-based for 49 (41%), II-based for 3 (3%), and
another regimen for 6 (5%). Four patients (3%) off ART had no subsequent ART initiation
recorded.
Baseline characteristics for the entire study population stratified by ART status at lymphoma
diagnosis are shown in Table 1. Statistically significant differences between the two groups
were noted with respect to histology, lymphoma stage, prior AIDS-defining illness, CD4
count, and HIV RNA. Median HIV viremia copy-6-months among those on ART was 2.22
log10 copies x 6-months/mL (IQR 1.54–3.50) versus 2.97 (IQR 2.33–4.14) for those off
ART (p<0.0001). Median HIV RNA values over time, for patients on and off ART, are
shown in Fig. 1 with interquartile ranges.
Among the 224 patients, 82 deaths occurred during 851 person-years of follow-up, yielding
a mortality rate of 9.6 deaths per 100 person-years [95% confidence interval (CI) 7.8–12.0].
Cumulative mortality for the entire study population was significantly different when
stratified by viremia copy-6-months below or above the median value (2.68 log10copies x 6-
months/mL), as shown in Fig. 2. Overall survival from six months to five years after
lymphoma diagnosis was 64% (95% CI 57–71%). Overall survival from six months to five
years after lymphoma diagnosis was 54% (95% CI 42–65%) and 70% (95% CI 61–79%)
among patients with viremia copy-6-months values above and below the median,
respectively (p=0.014).
Results of Cox proportional hazards modeling are shown in Table 2. The adjusted hazard
ratio (AHR) for mortality for HIV viremia copy-6-months was 1.35 (95% CI 1.11– 1.65),
suggesting that exposure to each additional 1-unit log10 increase in HIV RNA throughout
the six months after lymphoma diagnosis, was associated with a 35% increased risk of
subsequent death among six-month survivors. Other risk factors for mortality included older
age (AHR 1.37 per decade increase, 95% CI 1.03–1.83), lymphoma occurrence on ART
(AHR 1.63, 95% CI 1.02–2.63), and lower CD4 count at lymphoma diagnosis (AHR 0.75
per 100 cell/µlL increase, 95% CI 0.64–0.89).
When HIV RNA at lymphoma diagnosis was included in place of viremia copy-6-months,
each log10 increase was associated with an AHR for mortality of 1.11 (95% CI 0.91–1.34),
with other model estimates being similar. When HIV RNA six months after lymphoma
diagnosis was included in place of viremia copy-6-months, each log10 increase was
associated with an AHR for mortality of 1.32 (95% CI 1.12–1.56), with other model
estimates being similar. When dichotomous HIV RNA ≥400 copies/mL (i.e. unsuppressed
versus suppressed) at lymphoma diagnosis was included in place of viremia copy-6-months,
being unsuppressed was associated with an AHR for mortality of 1.45 (95% CI 0.78–2.67),
with other model estimates being similar. Likewise, when HIV RNA suppression six months
after lymphoma diagnosis was included in place of viremia copy-6-months, being
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unsuppressed was associated with an AHR for mortality of 1.64 (95% CI 1.03–2.63), with
other model estimates being similar. HIV RNA at lymphoma diagnosis and six months after
diagnosis were not analyzed together with viremia copy-6-months due to collinearity given
the short exposure window during which cumulative HIV viremia was defined. Model
estimates were additionally similar when nadir CD4 count was included in place of CD4
count at lymphoma diagnosis, and when cumulative viremia was assessed over nine rather
than six months after lymphoma diagnosis.
Lymphoma stage was recorded for 90 (40%) of patients overall, with 29 (32%) having stage
I/II disease and 62 (69%) having stage III/IV disease. In Cox proportional hazards modeling
in the subset of patients with known lymphoma stage, including all covariates as in Table 2
with the addition of stage (I/II versus III/IV), the AHR for mortality for HIV viremia
copy-6-months was 1.45 (95% CI 0.97–2.16), consistent with results in the entire study
population and with other model estimates being similar.
AHR estimates for the association between viremia copy-6-months and mortality, adjusted
for all covariates as in Table 2, are shown for the full analytic population as well as
predefined subgroups in Fig. 3. These analyses show consistent associations between early
cumulative HIV viremia and increased mortality, among patients on and off ART, across
CD4 strata, and among patients with NHL and HL.
Discussion
Our study is the first to examine effects of early HIV viremia on survival after HIV-
associated lymphoma. The results, drawn from a large multicenter HIV-infected cohort in
the United States, suggest that increased viremia during the six months after lymphoma
diagnosis is associated with an increased risk of death between six months and five years
after diagnosis. For each log10 increase in HIV RNA sustained over the six months
immediately after lymphoma diagnosis, we observed a 35% increase in mortality by five
years after lymphoma diagnosis. The significant association of mortality with viremia
copy-6-months, as well as cross-sectional HIV RNA six months after lymphoma diagnosis,
but not HIV RNA at lymphoma diagnosis, suggest that effective ART during chemotherapy
may improve overall survival. Although differences in early cumulative HIV viremia and
HIV RNA six months after lymphoma diagnosis may be influenced by patient and disease
characteristics other than ART, early and effective ART is likely to be the major factor
influencing HIV viremia after lymphoma diagnosis. The association between viremia
copy-6-months and increased mortality was consistent between patients on and off ART at
lymphoma diagnosis, those with NHL and HL, and across CD4 strata. Other variables
associated with mortality were older age, lymphoma occurrence on ART, and lower CD4
count. Our results are consistent with other preliminary data suggesting that concurrent ART
is associated with increased rates of complete remission and possibly overall survival among
patients with HIV-associated NHL [27].
In the absence of clear evidence, strategies for coadministering ART and chemotherapy have
varied, from concurrent ART during chemotherapy to sequential ART after chemotherapy
[5–8], with current guidelines making no strong recommendation for either approach [22].
Discontinuing or deferring ART until chemotherapy completion has resulted in long-term
survival of 60–70% for patients with HIV-associated NHL, when treated with the infusional
R-EPOCH regimen (rituximab, etoposide, predisone, vincristine, cyclophosphamide,
doxorubicin) [7,8,10], which may be superior to R-CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone) for patients with HIV [27,28]. Moreover, short-course
R-EPOCH developed at NCI is guided by interim response assessment, with an average
seven-week delay from chemotherapy initiation until resumption or initiation of ART, and
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only three chemotherapy cycles being administered in up to 70–80% of patients
demonstrated to have a complete response by fluorodeoxyglucose positron emission
tomography (FDG-PET) after two cycles [8,10]. However, results from this strategy have
been published for only 33 clinical trial participants treated at a single center, and without a
comparison group receiving identical chemotherapy with concurrent ART [8]. Additionally,
recent AMC studies have typically administered six cycles even when using R-EPOCH and
DR-COP (pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine,
prednisone) [6,9]. If strictly sequential ART after chemotherapy is recommended, this more
standard approach will result in longer periods off ART.
Patients with HIV-associated lymphoma continue to present with significant
immunosuppression in the ART era [5,7–9,20,21]. For most OIs, deferring ART by even 4–
10 weeks results in an increased risk of AIDS or death, suggesting that delaying ART for
weeks or months until chemotherapy is complete may not be inconsequential, particularly
for severely immunosuppressed patients [14– 17]. For patients receiving ART, episodic CD4
count-guided ART interruption has been shown in a randomized clinical trial to increase risk
of OI or death compared with continuous ART [29]. Although long-term effects of a single
fixed-duration ART interruption during chemotherapy remain unknown, short-term effects
of ART interruption include marked CD4 count decreases and HIV RNA increases [30–33].
Finally, in an analogous condition PTLD, consensus guidelines recommend reduction of
immunosuppression as initial therapy, which can lead to complete remissions even without
chemoimmunotherapy in some patients [22], again suggesting that early ART-mediated
immune reconstitution among HIV-infected lymphoma patients may be beneficial.
Concerns previously raised regarding interactions of ART with chemotherapy are based on
studies of older ART regimens [10–13], whereas current regimens typically include lower
ritonavir doses, newer agents such as integrase inhibitors, and agents for which
pharmacokinetic profiles are better defined. Studies proposing specific anti-apoptotic effects
of protease inhibitors likely reflect intracellular drug concentrations not achieved during
actual patient use [12,13], and contradict empirical demonstrations of protease inhibitor
antiproliferative effects in vitro against melanoma, lung cancer, and breast cancer cell lines,
by inhibition of signaling pathways involving phosphatidylinositol 3-kinase (PI3K), AKT,
and heat shock protein 90 (HSP90) [34–36].
The observation of increased mortality among patients developing lymphoma on ART has
been previously reported [21]. Lymphoma which develops on ART may be biologically
distinct from lymphoma occurring off ART, analogous to early and late PTLD, which differ
in EBV association, clinical behavior, and gene expression patterns [37–40]. Such
differences in tumor biology have not been investigated for HIV-associated lymphoma.
Other possible explanations include patients already on ARTat lymphoma diagnosis not
benefiting from positive effects on survival conferred by ART initiation, in addition to
lymphoma treatment. Exposure to ART at lymphoma diagnosis is also a marker of longer
duration of HIV infection and more advanced HIV illness, which may not be adequately
adjusted for by measures of HIV disease severity. Additionally, social and behavioral
differences impacting survival, including adherence, may exist between patients developing
lymphoma on and off ART.
Our research has several limitations. First, data are observational and estimates regarding
early HIV viremia effects on mortality may be subject to unmeasured confounding. Second,
detailed information regarding lymphoma treatment, stage, and other prognostic features
were not available for most patients. Third, cause of death was unknown, and our analyses
focused on overall survival, although patients with HIV-associated lymphoma are at risk for
competing causes of death. Finally, although drawn from one of the largest observational
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cohorts of patients with HIV-associated lymphoma, our analyses were restricted to a smaller
subset of patients in whom early cumulative HIV viremia after lymphoma diagnosis could
be reliably assessed, and who remained at risk for mortality six months after lymphoma
diagnosis.
Despite these limitations, our study has several strengths. To our knowledge, this is the first
study to examine the association between early HIV viremia and subsequent mortality after
lymphoma diagnosis. Patients studied represent a large and diverse HIV-infected population
in routine care across the United States. Mortality assessment used active and passive
surveillance, leading to near-complete ascertainment.
In conclusion, higher HIV viremia during the six months after lymphoma diagnosis was
associated with an increased risk of subsequent death in our analyses of United States HIV-
infected lymphoma patients surviving at least six months. These findings support treatment
strategies incorporating early ART with maximal HIV suppression, concurrently with
chemotherapy, for patients with HIV-associated lymphoma.
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Median HIV RNA and interquartile range for 224 HIV-infected adults in CNICS during the
6 months after lymphoma diagnosis, stratified by antiretroviral therapy (ART) status at
lymphoma diagnosis.
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Cumulative mortality after lymphoma diagnosis for 224 HIV-infected adults in CNICS,
stratified by HIV viremia copy-6 months (log10copies × 6-months/mL).
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Adjusted mortality hazard ratios for HIV viremia-copy-6 months among HIV-infected adults
in CNICS with lymphoma between 1996 and 2011, stratified by patient characteristics at
lymphoma diagnosis. ART, antiretroviral therapy; HL, Hodgkin lymphoma; NHL, non-
Hodgkin lymphoma.
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Table 1
Characteristics of 224 HIV-infected adults in CNICS with lymphoma between 1996 and 2011, stratified by
ART status at lymphoma diagnosis.
On ART Off ART p value
Total, n (%) 105 (46.9) 119 (53.1) –
Age (years) at lymphoma diagnosis, mean (SD) 44.2 (7.7) 42.4 (9.2) 0.12
Male, n (%) 99 (94.3) 109 (91.6) 0.44
Race/ethnicitya
  White, n (%) 59 (56.2) 59 (50.4) 0.39
  Black, n (%) 28 (26.7) 32 (27.4) 0.91
  Other, n (%) 18 (17.1) 26 (22.2) 0.34
Lymphoma diagnosis year, median (IQR) 2004 (2001–2007) 2004 (2002–2007) 0.82
Lymphoma category
  HL, n (%) 30 (28.6) 11 (9.2) 0.0002
  DLBCL, n (%) 45 (42.9) 61 (51.3) 0.21
  BL, n (%) 8 (7.6) 19 (16.0) 0.056
  PCNSL, n (%) 4 (3.8) 14 (11.8) 0.029
  Other NHL, n (%) 18 (17.1) 14 (11.8) 0.25
Lymphoma stage I/II, n (%)a 19 (47.5) 10 (19.6) 0.0046
Hepatitis B/C co-infection 22 (21.0) 30 (25.2) 0.45
AIDS illness prior to lymphoma diagnosis, n (%) 90 (85.7) 87 (73.1) 0.021
CD4 count (cells/µL) at lymphoma diagnosis, median (IQR)a 188 (78–339) 123 (49–287) 0.051
CD4 percentage at lymphoma diagnosis, median (IQR)a 18.0 (10.4–26.9) 11.3 (6.0–20.0) 0.0007
CD4 count (cells/µL) nadir, median (IQR)a 74 (27–198) 72 (29–153) 0.76
HIV RNA (log10copies/mL) at lymphoma diagnosis, median (IQR)a 2.30 (1.40–3.81) 4.83 (3.98–5.57) <0.0001
HIV RNA <400 copies/mL at lymphoma diagnosis, n (%)a 64 (63.4) 7 (6.1) <0.0001
HIV viremia copy-6-months (log10copies x 6-months/mL) 2.22 (1.54–3.50) 2.97 (2.33–4.14) <0.0001
ART, antiretroviral therapy; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; PCNSL, primary CNS
lymphoma.
a
N(%) missing observations on ART/off ART: Race/ethnicity=0(0%)/2(1.7%); Lymphoma stage¼65(61.9%)/68(57.1%); CD4 count at lymphoma
diagnosis=4(3.8%)/2(1.7%); CD4 percentage at lymphoma diagnosis=8(7.6%)/9(7.6%); CD4 count nadir=2(1.9%)/2(1.7%); HIV RNA at
lymphoma diagnosis=4(3.8%)/5(4.2%).
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Table 2
Adjusted mortality hazard ratios for 216 HIV-infected adults in the CNICS cohort with lymphoma between
1996 and 2011.a
Adjusted hazard ratio 95% CI p value
Male sex 1.72 0.56 – 5.25 0.34
Non-white ethnicity 0.65 0.40 – 1.04 0.074
Age at lymphoma diagnosis, per decade 1.37 1.03 – 1.83 0.033
Lymphoma diagnosis year
  1996–2000 Reference – –
  2001–2005 1.00 0.56 – 1.77 0.99
  2006–2009 1.13 0.56 – 2.29 0.74
Hepatitis B/C co-infection 1.25 0.71 – 2.18 0.44
AIDS illness prior to lymphoma diagnosis 1.16 0.66 – 2.07 0.61
ART at lymphoma diagnosis 1.63 1.02 – 2.63 0.043
CD4 count at lymphoma diagnosis, per 100 cells/µL 0.75 0.64 – 0.89 0.0008
Lymphoma category
  PCNSL (reference) – – –
  HL 0.45 0.14 –1.44 0.18
  DLBCL 0.94 0.38 – 2.32 0.89
  BL 0.93 0.26 – 3.31 0.92
  Other NHL 0.85 0.31 – 2.34 0.75
HIV viremia copy-6-months (log10copies ×6-months/mL) 1.35 1.11 – 1.65 0.0029
ART, antiretroviral therapy; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin lymphoma; NHL, Non-Hodgkin
lymphoma; PCNSL, primary CNS lymphoma.
a
8 of 224 patients (3.6%) with missing data were excluded from Cox proportional hazards modeling.
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